Overview

Nivolumab With Standard of Care Chemotherapy for Peripheral T Cell Lymphomas

Status:
Active, not recruiting
Trial end date:
2021-12-01
Target enrollment:
Participant gender:
Summary
This regimen aims to become the first line treatment for peripheral T cell lymphoma, using nivolumab with the standard of care chemotherapy.
Phase:
Phase 1/Phase 2
Details
Lead Sponsor:
University of Colorado, Denver
Treatments:
Antibodies, Monoclonal
Nivolumab